诺华（Novartis）今年第三次上调了全年业绩指引，此前得益于其关键药物收入的提振，该公司第三季度利润和销售额实现增长并超过分析师预期。

　　这家瑞士制药巨头周二表示，目前预计2024年核心营业利润增幅将在10-20%区间的高段，此前该公司预期增幅在此区间的中、高段。

　　诺华目前预计全年销售额将实现低两位数增幅，此前该公司的预期为高个位数至低两位数增幅。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：陈钰嘉

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.